Develops, manufactures and sells branded and generic medicines, over-the-counter products and medical devices for health care providers, pharmacies and patients.
10-K for FY2025, filed Feb 19, 2026Bausch Health Companies Inc. (“we”, “us”, “our”, the “Company” or “Bausch Health”) is a global, diversified specialty pharmaceutical and…View ↗
The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan® product line currently represent approximately 85% of…View ↗
Our Bausch + Lomb business is a fully integrated eye health business with a portfolio of established lines of contact lenses, intraocular…View ↗
Wholesalers and some pharmacy chains buy medicines, over-the-counter products and medical devices; product sales are generally completed when customers obtain the goods. Other revenue comes from licensing, co-promotion and contract manufacturing services.
10-K for FY2025, filed Feb 19, 2026The Company’s revenues are primarily generated from product sales, primarily in the therapeutic areas of GI, hepatology, neurology…View ↗
A contract with the Company’s customers exists for each product sale. Where a contract with a customer contains more than one performance…View ↗
The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart. The Company…View ↗
10-K for FY2025, filed Feb 19, 2026
FY2025 revenue by product or service ↗$10.3B
10-K for FY2025, filed Feb 19, 2026
$10.3B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
99%
FY2022: 99%
|
Product sales, FY2025
$10.2B Sources
|
Sold outright |
|
Other revenues
|
1.1%
FY2022: 1.2%
|
Other revenues, FY2025
$110M Sources
|
Pharmaceuticals are promoted to physicians and hospitals through the company's sales force, but products are sold mainly to wholesalers and sometimes to large pharmacy chains. In some markets it sells directly to physicians, hospitals and large drug-store chains; elsewhere it uses distributors.
10-K for FY2025, filed Feb 19, 2026
Yes. It kept 2 cents of every revenue dollar as net income in FY2025 and turned 10 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
8-K, filed Jul 29, 2026
BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCEView ↗
Growing. Revenue grew 22% in 4 years, from $8.4B in FY2021 to $10.3B in FY2025, about 5% a year.
Loading...